A clinical-stage biopharmaceutical company sought to develop an optimized portfolio strategy. It sought Putnam’s guidance to prioritize asset-level strategies through a holistic review of options.
We generated a comprehensive list of asset opportunities and portfolio options and prioritized 18 programs by applying pre-agreed criteria, defining the value of each opportunity, creating revenue streams with market criteria, and facilitating working sessions to align on critical assumptions.
Our portfolio recommendations addressed the enterprise goals of being best-in-class, maximizing economic value, achieving optimal timing, and minimizing risk over time and across geographies.
Jump to a slide with the slide dots.
Refined HCP targeting in rare disease using integrated data, boosting hit rates from 10% to 50% and delivering 3x ROI in 6 months.
Read moreUsed GenAI to benchmark digital voice in oncology, boosting engagement & leadership via LinkedIn, DEI & clinical messaging.
Read moreFuture-proofed data strategy with Putnam: gaps identified, vendors vetted, leading to a first US multi-source tokenized DB.
Read more